The Scott M. Hammer Annual Update on HIV Management in New York, New York

The Scott M. Hammer Annual Update on HIV Management in New York, New York

Registration Details

  • In-Person Registration: $95.00 (USD)
  • In-Person Registration ends: Monday, June 6, 2022
  • In-Person Fellows: $25.00 (USD)
  • In-Person Fellows ends: Monday, June 6, 2022
  • Virtual Registration: $35.00 (USD)
  • Virtual Registration ends: Monday, June 13, 2022
  • Virtual Fellows: $25.00 (USD)
  • Virtual Fellows ends: Monday, June 13, 2022

Faculty

Elaine J. Abrams, MD
Columbia University
Carlos del Rio, MD
Emory University School of Medicine
Gerald H. Friedland, MD
Yale University School of Medicine
Richard Koup, MD
Vaccine Research Center, NIAID, NIH
Chloe M. Orkin, MBBCH, MSc
Queen Mary University
Paul E. Sax, MD
Harvard Medical School
Paul A. Volberding, MD
University of California San Francisco

Special Panelists

Kathryn Anastos, MD
Albert Einstein College of Medicine
Donna C. Futterman, MD
The Albert Einstein College of Medicine
Sheldon Landesman, MD
SUNY Downstate
Fred T. Valentine, MD
New York University

June 13, 2022

9:30 AM - 4:30 PM ET

Address

NYU Skirball Center
566 LaGuardia Pl
New York
New York
United States

For in-person attendees, there is a special panel session at the close of the course:

Special Panel Session: 40 Years Later: Looking Back at the Beginning of the HIV/AIDS Epidemic in New York. From the Perspectives of People Who Were There From the Beginning

Moderator: Gerald Friedland, MD
Panelists:
Kathryn Anastos, MD, Donna Futterman, MD, Sheldon Landesman, MD, and Fred T. Valentine, MD

For those attending in person, proof of vaccination and wearing a mask at all times during the course will be required, as well as any other measure(s) the IAS–USA sets forth to help us ensure our attendees are safe.

The NYU Skirball requires proof of being fully vaccinated and boosted.  Documentation, by card, a photo on your phone, or using the NYS Excelsior pass, must include:

  • Name
  • Birthdate
  • Dates of doses
  • Vaccine manufacture
  • Documentation is in English

For more detailed information click here.

NYS Excelsior pass – click here

List of Topics

  • The Evolution of mRNA Vaccines: Implications for an HIV Vaccine
  • CROI 2022 Review and Highlights
  • New Drugs, Platforms, and Schedules for Treatment and Prevention of HIV Infection
  • Antiretroviral Therapy Case-Based Panel Discussion
  • The Clinical Relationship Between HIV and COVID-19
  • Special Panel Session: 40 Years of Progress: Looking Back at the Start of the HIV Epidemic in New York

Agenda

Last Modified: May 20, 2022 @ 10:13 AM

Program Description

This live course will consist of an in-person component as long as it is safe and practical to do so. There will also be a simultaneous virtual component for those unable to travel.

This live course will focus on recent advances in HIV medicine including updates from CROI 2022, new antiretroviral formulations and strategies, the implications of mRNA vaccines for an HIV vaccine, and the clinical relationship between HIV and COVID-19. This course will feature a case-based panel discussion on antiretroviral.

For in-person attendees, there is a special panel session at the close of the course, “Looking Back at the Beginning of the HIV/AIDS Epidemic in New York, New York.”

For those attending in person, proof of vaccination and wearing a mask at all times during the course will be required, as well as any other measure(s) the IAS–USA sets forth to help us ensure our attendees are safe.

Assessment of Needs

Rapid advances in HIV disease management and COVID-19 information require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV and COVID-19. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be better able to:

  • Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Describe the most current data from recent scientific conferences, including research on new and investigational antiretroviral drugs
  • Describe the clinical relationship between HIV and COVID-19, including clinical outcomes, vaccine responses, and long COVID
  • Describe the implications of recent advances of mRNA vaccines for developing an HIV vaccine

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV or COVID-19 research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 8 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

BRONZE SUPPORTER

Theratechnologies, Inc.

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.